Advertisement

Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy

  • Henry N Ginsberg
    Correspondence
    Address for reprints: Henry N. Ginsberg, MD, Irving Center for Clinical Research, 630 West 168th Street, New York, New York 10032
    Affiliations
    Division of Preventive Medicine and Nutrition, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Search for articles by this author
      It has long been recognized that elevated triglyceride levels are associated with increased risk for coronary heart disease (CHD). However, it has not been determined whether elevated triglycerides are an independent risk factor for CHD. Thus, the predictive power of triglyceride levels are often reduced or lost when other risk factors, particularly high-density lipoprotein (HDL) cholesterol or diabetes mellitus, are taken into account.
      • Austin M.A.
      Plasma triglyceride and coronary heart disease.
      ,
      NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease
      Triglyceride, high-density lipoprotein, and coronary heart disease.
      A number of recent findings, however, have provided compelling evidence of the independent association of elevated triglycerides and major coronary events, including a meta-analysis documenting an independent incremental risk of such events with triglyceride elevation.
      • Hokanson J.E.
      • Austin M.A.
      Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol a meta-analysis of population-based prospective studies.
      ,
      • Austin M.A.
      • Hokanson J.E.
      • Edwards K.L.
      Hypertriglyceridemia as a cardiovascular risk factor.
      A persistent caveat is, however, the lack of clear identification of diabetic subjects in these studies.
      To read this article in full you will need to make a payment

      References

        • Austin M.A.
        Plasma triglyceride and coronary heart disease.
        Arterioscler Thromb Vasc Biol. 1991; 11: 2-14
        • NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease
        Triglyceride, high-density lipoprotein, and coronary heart disease.
        JAMA. 1993; 269: 505-510
        • Hokanson J.E.
        • Austin M.A.
        Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol.
        J Cardiovasc Risk. 1996; 3: 213-219
        • Austin M.A.
        • Hokanson J.E.
        • Edwards K.L.
        Hypertriglyceridemia as a cardiovascular risk factor.
        Am J Cardiol. 1998; 81: 7B-12B
        • Assmann G.
        • Schulte H.
        • von Eckardstein A.
        Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men.
        Am J Cardiol. 1996; 77: 1179-1184
        • Manninen V.
        • Tenkanen L.
        • Koskinen P.
        • Huttunen J.K.
        • Mänttäri M.
        • Heinonen O.P.
        • Frick M.H.
        Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study.
        Circulation. 1992; 85: 37-45
        • Stampfer M.J.
        • Krauss R.M.
        • Ma J.
        • Blanche P.J.
        • Holl L.G.
        • Sacks F.M.
        • Hennekens C.H.
        A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
        JAMA. 1996; 276: 882-888
        • Gardner C.D.
        • Fortmann S.P.
        • Krauss R.M.
        Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.
        JAMA. 1996; 276: 875-881
        • Miller B.D.
        • Alderman E.L.
        • Haskell W.L.
        • Fair J.M.
        • Krauss R.M.
        Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.
        Circulation. 1996; 94: 2146-2153
        • Lamarche B.
        • Tchernof A.
        • Moorjani S.
        • Cantin B.
        • Dagenais G.R.
        • Lupien P.J.
        • Després J-P.
        Small, dense low-density lipoprotein particles a predictor of the risk of ischemic heart disease in men.
        Circulation. 1997; 95: 69-75
        • Jeppesen J.
        • Hein H.O.
        • Suadicani P.
        • Gyntelberg F.
        Triglyceride concentration and ischemic heart disease.
        Circulation. 1998; 97: 1029-1036
        • Zilversmit D.B.
        Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins.
        Clin Chem. 1995; 41: 153-158
        • Vogel R.A.
        • Corretti M.C.
        • Plotnick G.D.
        Effect of a single high-fat meal on endothelial function in healthy subjects.
        Am J Cardiol. 1997; 79: 350-354
        • Fard A.
        • Tuck C.
        • Donis J.A.
        • Sciacca R.
        • Di Tullio M.R.
        • Wu H.
        • Bryant T.A.
        • Chen N-T.
        • Torres-Tamayo M.
        • Ramasamy R.
        • et al.
        Plasma asymmetric dimethylarginine levels are acutely elevated and endothelial function is impaired after a high-fat mean in patients with type 2 diabetes.
        Arterio Thromb Vasc Biol. 2000; 20: 2039-2044
        • Ginsberg H.N.
        • Jones J.
        • Blaner W.S.
        • Thomas A.
        • Karmally W.
        • Fields L.
        • Blood D.
        • Begg M.D.
        Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women.
        Arterioscler Thromb Vasc Biol. 1995; 15: 1829-1838
        • Sharrett A.R.
        • Chambless L.E.
        • Heiss G.
        • Paton C.C.
        • Patsch W.
        Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women.
        Arterioscler Thromb Vasc Biol. 1995; 15: 2122-2129
        • Austin M.A.
        • King M.C.
        • Vranizan K.M.
        • Krauss R.M.
        Atherogenic lipoprotein phenotype.
        Circulation. 1990; 82: 495-506
        • Tribble D.L.
        • van den Berg J.J.
        • Motchnick P.A.
        • Ames B.N.
        • Lewis D.M.
        • Chait A.
        • Krauss R.M.
        Oxidative susceptibility of low-density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content.
        Proc Natl Acad Sci USA. 1994; 91: 1183-1187
        • Camejo G.
        • Hurt-Camejo E.
        • Wiklund O.
        • Bondjers G.
        Association of apoB lipoproteins with arterial proteoglycans.
        Atherosclerosis. 1998; 139: 205-222
        • Tall A.R.
        • Jiang X.C.
        • Luo Y.
        • Silver D.
        George Lyman Duff Memorial Lecture.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1185-1188
        • Chait A.
        • Albers J.J.
        • Brunzell J.D.
        Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia.
        Eur J Clin Invest. 1980; 10: 17-22
        • Kissebah A.H.
        • Alfarsi A.
        • Adams P.W.
        Integrated regulation for very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man.
        Metabolism. 1981; 20: 856-868
        • Arad Y.
        • Ramakrishnan R.
        • Ginsberg H.N.
        Lovastatin therapy reduces low density lipoprotein apolipoprotein B levels in patients with combined hyperlipidemia by reducing the direct production of low density lipoprotein apolipoprotein B.
        J Lipid Res. 1990; 31: 567-582
        • Kissebah A.H.
        • Alfarsi S.
        • Evans D.J.
        Low density lipoprotein metabolism in familial combined hyperlipidemia.
        Arteriosclerosis. 1984; 4: 614-624
        • Janus E.D.
        • Nicoll A.
        • Wootton R.
        • Turner P.R.
        • Magill P.J.
        • Lewis B.
        Quantitative studies of very low density lipoprotein.
        Eur J Clin Invest. 1980; 10: 149-159
        • Teng B.
        • Sniderman A.D.
        • Soular A.K.
        • Thompson G.R.
        Metabolic basis of hyperapobetalipoproteinemia.
        J Clin Invest. 1986; 77: 663-672
        • Ginsberg H.N.
        • Ngai C.
        • Wang X-J.
        • Ramakvishnan R.
        Increased production rates of low-density lipoproteins are common in individuals with low plasma levels of high-density lipoprotein cholesterol, independent of plasma triglyceride concentrations.
        Arterioscler Thromb Vasc Biol. 1993; 13: 842-851
        • Packard C.J.
        • Demant T.
        • Stewart J.P.
        • Bedford D.
        • Casslake M.J.
        • Schwertfeger G.
        • Bedynek A.
        • Shepherd J.
        • Seidel D.
        Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
        J Lipid Res. 2000; 41: 305-318
        • Reaven G.M.
        Role of insulin resistance in human disease.
        Diabetes. 1988; 37: 1595-1607
        • Laws A.
        • Reaven G.M.
        Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations.
        J Intern Med. 1992; 231: 25-30
        • Després J-P.
        • Lamarche B.
        • Mauriège P.
        • Cantin B.
        • Dagenais G.R.
        • Moorjani S.
        • Lupien P-J.
        Hyperinsulinemia as an independent risk factor for ischemic heart disease.
        N Engl J Med. 1996; 334: 952-957
        • Welborn T.A.
        • Wearne K.
        Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations.
        Diabetes Care. 1979; 2: 154-160
        • Pyoralla K.
        • Savolainen E.
        • Kaukola S.
        • Haapakoski J.
        Plasma insulin as coronary heart disease risk factor.
        Acta Med Scand. 1985; 701: 38-52
        • Austin M.A.
        • Mykkanen L.
        • Kuusisto J.
        • Edwards K.L.
        • Nelson C.
        • Haffner S.M.
        • Pyörälä K.
        • Laakso M.
        Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women.
        Circulation. 1995; 92: 1770-1778
        • Reaven G.M.
        • Chen Y.D.
        • Jeppesen J.
        • Maheux P.
        • Krauss R.M.
        Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles.
        J Clin Invest. 1993; 92: 141-146
        • Grundy S.M.
        • Vega G.L.
        Two different views of the relationship of hypertriglyceridemia to coronary heart disease.
        Arch Intern Med. 1992; 152: 28-34
        • National Cholesterol Education Program
        Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults.
        Circulation. 1994; 89: 1333-1445
        • Ginsberg H.N.
        Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer.
        Ann Intern Med. 1997; 126: 912-914
        • Coronary Drug Project Research Group
        Clofibrate and niacin in coronary heart disease.
        JAMA. 1975; 231: 360-381
        • Blankenhorn D.H.
        • Nessim S.A.
        • Johnson R.L.
        • Sanmarco M.E.
        • Azen S.P.
        • Cashin-Hemphill L.
        Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
        JAMA. 1987; 19: 3233-3240
        • Brown G.
        • Albers J.J.
        • Fisher L.D.
        • Schaefer S.M.
        • Lin J-T.
        • Kaplan C.
        • Zhao X.Q.
        • Bisson B.D.
        • Fitzpatrick V.F.
        • Dodge H.T.
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N Engl J Med. 1990; 323: 1289-1298
        • Frick M.H.
        • Elo H.
        • Haapa K.
        • Heinonen O.P.
        • Heinsalmi P.
        • Helo P.
        • Huttunen J.K.
        • Kaitaniemi P.
        • Koskinen P.
        • Manninen V.
        • et al.
        • Helsinki Heart Study
        Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
        N Engl J Med. 1987; 317: 1237-1245
        • Rubins H.B.
        • Robins S.J.
        • Collins D.
        • Fye C.L.
        • Anderson J.W.
        • Elam M.B.
        • Faas F.H.
        • Linares E.
        • Schaefer E.J.
        • Schectman G.
        • Wilt T.J.
        • Wittes J.
        • for the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
        N Engl J Med. 1999; 341: 410-418
        • Grundy S.M.
        Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
        Circulation. 1997; 95: 1-4
        • Bakker-Arkema R.G.
        • Davidson M.H.
        • Goldstein R.J.
        • Davignon J.
        • Isaacsohn J.L.
        • Weiss S.R.
        • Keilson L.M.
        • Brown W.V.
        • Miller V.T.
        • Shurzinske L.J.
        • Black D.M.
        Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
        JAMA. 1996; 275: 128-133
        • Davidson M.H.
        • Stein E.A.
        • Dujovne C.A.
        • Hunninghake D.B.
        • Weiss S.R.
        • Knopp R.H.
        • Illingworth D.R.
        • Mitchel Y.B.
        • Melino M.R.
        • Zupkis R.V.
        • Dobrinska M.R.
        • Amin R.D.
        • Tobert J.A.
        The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
        Am J Cardiol. 1997; 79: 38-42
        • Jones P.
        • Kafonek S.
        • Laurora I.
        • Hunninghake D.B.
        • for the CURVES Investigators
        Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study).
        Am J Cardiol. 1998; 81: 582-587
        • Stein E.A.
        • Lane M.
        • Laskarzewski P.
        Comparison of statins in hypertriglyceridemia.
        Am J Cardiol. 1998; 81: 66B-69B
        • Ooi T.C.
        • Heinonen T.
        • Alaupovic P.
        • Davignon J.
        • Leiter L.
        • Lupien P.J.
        • Sniderman A.D.
        • Tan M.H.
        • Tremblay G.
        • Soisky A.
        • Shurzinske L.
        • Black D.M.
        Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia.
        Arterioscler Thromb Vasc Biol. 1997; 17: 1793-1799
        • Tikkanen M.J.
        • Laakso M.
        • Ilmonen M.
        • Helve E.
        • Kaarsalo E.
        • Kilkki E.
        • Saltevo J.
        Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM.
        Diabetes Care. 1998; 21: 477-481
        • East C.
        • Bilheimer D.W.
        • Grundy S.M.
        Combination drug therapy for familial combined hyperlipidemia.
        Ann Intern Med. 1988; 109: 25-32
        • Illingworth D.F.
        • Bacon S.
        Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
        Circulation. 1989; 79: 590-596
        • Ellen R.L.B.
        • McPherson R.
        Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
        Am J Cardiol. 1998; 81: 60B-65B
        • Shepherd J.
        Fibrates and statins in the treatment of hyperlipidaemia.
        Eur Heart J. 1995; 16: 5-13
        • Carlson L.A.
        • Rosenhamer G.
        Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
        Acta Med Scand. 1988; 223: 405-418
        • American Diabetes Association
        Management of dyslipidemia in adults with diabetes.
        Diabetes Care. 2000; 23: 557-565
        • Assmann G.
        • Schulte H.
        Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience).
        Am J Cardiol. 1992; 70: 733-737